Vanguard Group Inc. Grows Stake in Bausch Health Cos Inc. $BHC

Vanguard Group Inc. raised its stake in shares of Bausch Health Cos Inc. (NYSE:BHC) by 4.0% in the third quarter, Holdings Channel reports. The institutional investor owned 12,241,072 shares of the company’s stock after buying an additional 470,968 shares during the quarter. Vanguard Group Inc.’s holdings in Bausch Health Cos were worth $78,808,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in BHC. Paulson & CO. Inc. boosted its stake in shares of Bausch Health Cos by 24.0% in the 2nd quarter. Paulson & CO. Inc. now owns 32,791,702 shares of the company’s stock worth $218,393,000 after buying an additional 6,352,667 shares during the last quarter. Acadian Asset Management LLC raised its holdings in Bausch Health Cos by 16.2% in the 2nd quarter. Acadian Asset Management LLC now owns 782,386 shares of the company’s stock worth $5,193,000 after purchasing an additional 109,070 shares during the period. Goldentree Asset Management LP lifted its position in Bausch Health Cos by 13.2% during the second quarter. Goldentree Asset Management LP now owns 34,254,889 shares of the company’s stock valued at $227,848,000 after purchasing an additional 4,004,889 shares in the last quarter. Maple Rock Capital Partners Inc. grew its holdings in Bausch Health Cos by 14.9% during the second quarter. Maple Rock Capital Partners Inc. now owns 7,808,487 shares of the company’s stock valued at $52,005,000 after purchasing an additional 1,010,987 shares during the period. Finally, SG Americas Securities LLC increased its position in Bausch Health Cos by 114.4% in the second quarter. SG Americas Securities LLC now owns 6,152,986 shares of the company’s stock worth $40,979,000 after buying an additional 3,282,684 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors.

Bausch Health Cos Trading Down 1.2%

BHC opened at $5.56 on Friday. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of 13.24 and a beta of 0.37. The company has a current ratio of 1.47, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68. The stock has a fifty day moving average price of $6.41 and a 200-day moving average price of $6.64. Bausch Health Cos Inc. has a 12 month low of $4.25 and a 12 month high of $8.69.

Bausch Health Cos (NYSE:BHC) last released its quarterly earnings results on Wednesday, February 18th. The company reported $1.08 earnings per share for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.13). Bausch Health Cos had a net margin of 1.53% and a return on equity of 875.00%. The firm had revenue of $2.78 billion during the quarter, compared to the consensus estimate of $2.71 billion. As a group, equities research analysts anticipate that Bausch Health Cos Inc. will post 4.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on BHC. Truist Financial boosted their price objective on Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a research report on Wednesday, January 7th. Weiss Ratings downgraded shares of Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research note on Thursday, February 19th. Wall Street Zen cut shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 15th. Barclays decreased their target price on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 25th. Finally, Raymond James Financial reaffirmed a “market perform” rating on shares of Bausch Health Cos in a report on Monday, January 26th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Bausch Health Cos has an average rating of “Reduce” and a consensus price target of $8.33.

Bausch Health Cos Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.